Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1316915 | 0.75 | MEN1 (0.44) | TNKS2SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL11812669 | 0.75 | CYP2C19 (0.45) | TNKS2SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL15604879 | 0.75 | — | — | |
| SCHEMBL18125709 | 0.75 | CYP2C19 (0.45) | TNKS2SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL9580047 | 0.74 | PRCP (0.36) | TNKS2MEN1KMT2ANPC1HTR2B | |
| SCHEMBL10738168 | 0.73 | CHRNA7 (0.39) | TNKS2SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL10231026 | 0.72 | ALDH1A1 (0.46) | TNKS2MEN1KMT2ACYP3A4LMNA | |
| SCHEMBL14889198 | 0.72 | MEN1 (0.42) | MEN1KMT2ACYP3A4MAPTLMNA | |
| SCHEMBL6259561 | 0.72 | TNKS2 (0.57) | TNKS2SMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL2524847 | 0.71 | CHRNB2 (0.52) | SMN1; SMN2MEN1KMT2ACYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9316368-A | — | — | None | — | — | JP | disclosed |
| US-9290517-B2 | Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150284411-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-10-08 | — | — | US | disclosed |
| WO-2015099483-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME | 주식회사 두산 | 2015-07-02 | — | — | WO | disclosed |
| EP-2888005-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014031515-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2011079118-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079114-A1 | PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| JP-H09316368-A | THERMOSETTING EPOXY POWDER COATING MATERIAL FOR METAL PIPE AND COATED METAL PIPE USING THE SAME | KANSAI PAINT CO LTD | 1997-12-09 | — | — | JP | disclosed |
| EP-0575425-A1 | USE OF OXAZOLO- 2,3-a]ISOINDOLE AND IMIDAZO 2,1-a]ISOINDOLE DERIVATIVES AS ANTIVIRAL DRUGS, AND NEW OXAZOLO 2,3-a]ISOINDOLE DERIVATIVES. | BOEHRINGER MANNHEIM GMBH (DE) | 1993-12-29 | — | — | EP | disclosed |
| WO-1992016207-A1 | USE OF OXAZOLO-[2,3-a]ISOINDOLE AND IMIDAZO[2,1-a]ISOINDOLE DERIVATIVES AS ANTIVIRAL DRUGS, AND NEW OXAZOLO[2,3-a]ISOINDOLE DERIVATIVES | BOEHRINGER MANNHEIM GMBH (DE) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284411-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[E,2-B]FURAN DERIVATIVES | PRKAG2, PRKAB2, PRKAG1 | TNKS2 904/4885SMN1; SMN2 4833/4885MEN1 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.